Status:

COMPLETED

An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

Lead Sponsor:

Xijing Hospital

Conditions:

Chemotherapy-Induced Nausea and Vomiting

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This clinical study was designed to demonstrate that a single, intravenous dose of palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed CINV and was also well tole...

Eligibility Criteria

Inclusion

  • Male or female, age ranging from 18 yrs to 70 yrs, with histologically or cytologically confirmed malignant disease
  • naive to chemotherapy or nonnaive with an interval of at least 14 days to the last one
  • Karnofsky index more than 70% and anticipated survival time more than 90 days
  • Scheduled to receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2) on study Day 1 and the chemotherapy should be accomplished on study Day 1
  • No emetic episodes and antiemetic medication during the 24 hours preceding chemotherapy administration
  • Adequate organ functions(No impairment to renal, hepatic, cardiac or bone marrow function )
  • Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit
  • Provision of written informed consent

Exclusion

  • Inability to understand or cooperate with study procedures
  • Receipt of investigational drugs 30 days before study entry
  • Scheduled to receive any drug with antiemetic efficacy from 24 hrs before to 5 days after treatment
  • Contraindications to 5-HT3 receptor antagonists
  • Woman Patient with Pregnancy or lactation
  • Diagnosed with hypertension or severe infectious diseases
  • Obstructive symptom of gastrointestinal tract
  • Symptomatic brain metastasis or mental dysfunction
  • Baseline QTc \> 500 ms

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

208 Patients enrolled

Trial Details

Trial ID

NCT00666783

Last Update

April 25 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xijng Hospital

Xi'an, Shaanxi, China, 710032